Comparison of p53 and CD44 variant 6 expression between paired primary and recurrent ovarian cancer: An immunohistochemical analysis

Oncology Reports

Volumn 6, Issue 1, 1999, Pages 97-101

  Kamura, Toshiharu ^a   Sakai, Kunihiro ^a   Kaku, Tsunehisa ^a   Kobayashi, Hiroaki ^a   Mitsumoto, Masamune ^a   Tsuneyoshi, Masazumi ^a   Nakano, Hitoo ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

CD44v6; Immunohistochemical staining; Ovarian cancer; p53; Tumor progression

Indexed keywords

ANTINEOPLASTIC AGENT; CD44V6 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; GLYCOPROTEIN; HERMES ANTIGEN; PROTEIN P53; TUMOR PROTEIN;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CHEMISTRY; COLLOID CARCINOMA; COMPARATIVE STUDY; CYSTADENOCARCINOMA; DISEASE COURSE; ENDOMETRIOID CARCINOMA; FEMALE; HUMAN; METASTASIS; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; ANTIGENS, CD44; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, ENDOMETRIOID; CISPLATIN; CYCLOPHOSPHAMIDE; CYSTADENOCARCINOMA, PAPILLARY; DISEASE PROGRESSION; EPIRUBICIN; FEMALE; GENES, P53; GLYCOPROTEINS; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032615590     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.6.1.97     Document Type: Article

References (20)

1. Tsuruchi N, Kamura T, Tsukamoto N, Akazawa K, Saito T, Kaku T, To N and Nakano H: Relationship between paraaortic lymph node involvement and intraperitoneal spread in patients with ovarian cancer. Gynecol Oncol 49, 51-55, 1993.
2. Chu TM, Lin TH and Kawinski E: Detection of soluble P-glycoprotein in culture media and extracellular fluids. Biochem Biophys Res Commun 203: 506-512, 1994.
3. Bourhis J, Goldstein LJ, Riou G, Pastan I, Gottesman MM and Benard J: Expression of a human multidrug resistance gene in ovarian carcinomas. Cancer Res 49: 5062-5065, 1989.
4. Rutledge ML, Robey-Cafferty SS, Silva EG and Bruner JM: Monoclonal antibody C219 detection of the multidnig-resistant protein P-glycoprotein in routinely processed tissues: a study of 36 cases of ovarian carcinoma. Mod Pathol 3: 298-301, 1990.
5. Banks L, Matlashewski G and Crawford L: Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression. Eur J Biochem 159: 529-534, 1986.
6. Screaton GR, Bell MV, Bell JI and Jackson DG: The identification of a new alternative exon with highly restricted tissue expression in transcripts encoding the mouse Pgp-1(CD44) homing receptor. Comparison of all 10 variable exons between mouse, human, and rat. J Biol Chem 268: 12235-12238, 1993.
7. Amada S, Nakano H and Tsuneyoshi M: Leiomyosarcoma versus bizarre and cellular leiomyomas of the uterus: a comparative study based on the MIB-1 and proliferating cell nuclear antigen indices, p53 expression, DNA flow cytometry, and muscle specific actins. Int J Gynecol Pathol 14: 134-142, 1995.
8. Mann HB and Whitney DR: On a test of whether one of two random variables is stochastically larger than the other. Ann Math Stat 18: 50-60, 1947.
9. Levine AJ, Momand J and Finlay CA: The p53 tumour suppressor gene. Nature 351: 453-456, 1991.
10. Hollstein M, Sidransky D, Vogelstein B and Harris CC: p53 mutations in human cancers. Science 253: 49-53, 1991.
11. Harris CC and Hollstein M: Clinical application of the p53 tumor suppressor gene. N Engl J Med 329. 1318-1327, 1993.
12. Hassapoglidou S, Diammandis EP and Autherland DJA: Quantification of protein in tumor cell lines, breast tissue extracts and serum with time-resolved immunofluorometry. Oncogene 8: 1501-1509, 1993.
13. Perego P, Gialola M, Gighetti SC, Supino R, Caserini C, Delia D, Pierotti MA, Miyasnita T, Reed JC and Zunino F: Association between cisplatin resistance and mutation of p53 gene and reduced Bax expression in ovarian carcinoma cell system. Cancer Res 56: 556-562, 1996.
14. Joensuu H, Klemi PJ, Toikkanen S and Jalkanen S: Glycoprotein CD44 expression and its association with survival in breast cancer. Am J Pathol 143: 867-874, 1993.
15. Mayer B, Jauch KW, Gunthert U, Figdor CG, Schildverg FW, Funke I and Johnson JP: De novo expression of CD44 and survival in gastric cancer. Lancet 342: 1019-1022, 1993.
16. Kainz C, Kohlberger P, Sluitz G, Tempfer C, Heinzl H, Reinhaller A, Breitenecker G and Koelbl H: Splice variants of CD44 in human cervical cancer stage IB to IIB. Gynecol Oncol 57: 383-387, 1995.
17. Uho-Steidi M, Muller-Holzner E, Zeimet AG, Adolf GR, Daxenbichler G, Marth C and Dapunt O: Prognostic value of CD44 splice variant expression in ovarian cancer. Oncology 52: 400-406, 1995.
18. Cannistra SA, Abu-Jawdeh G, Miloff J, Strobel T, Swanson L, Andersen J and Ottensmeier C: CD44 variant expression is a common feature of epithelial ovarian cancer: lack of association with standard prognostic factors. J Clin Oncol 13: 1912-1921, 1995.
19. Canninstra SA, Kansas GS, Niloff J, DeFranzo B, Kim Y and Ottensmeier C: Binding of ovarian cancer cells to peritoneal mesothelium in vitro is partly mediated by CD44H. Cancer Res 53: 3830-3838, 1993.
20. Jones LM, Gardner MJ, Catterall JB and Turner GA: Hyaluronic acid secreted by mesothelial cells: a natural barrier to ovarian cancer cell adhesion. Clin Exp Metastasis 13: 373-380, 1995.